14.12.18

NUEVOLUTION PROVIDES UPDATE ON THE POSITIVE PROGRESS IN PARTNERSHIPS & PIPELINE AND CONSOLIDATION OF ITS BUSINESS & PATENT STRATEGY

28.11.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE THIRD QUARTER OF 2018

28.11.18

AMGEN EXERCISES ITS OPT-IN RIGHT IN THE SECOND PRECLINICAL CANCER PROGRAM FROM THE NUEVOLUTION COLLABORATION

11.10.18

NUEVOLUTION TO PRESENT DATA FROM ITS DISCOVERY PROGRAM DIRECTED AT TARGETING THE KEY DISEASE INFLAMMATORY SIGNALING MOLECULE, INTERLEUKIN-17A (IL-17A)  

31.08.18

NUEVOLUTION APPOINTS JOHNNY STILOU AS CHIEF FINANCIAL OFFICER

22.08.18

NUEVOLUTION DISCLOSES THE IDENTITY OF ITS “CYTOKINE X” PROGRAM BEING INTERLEUKIN IL-17A, AND INITIATES PROMOTION OF ITS SMALL MOLECULE IL-17A INHIBITOR PROGRAM TARGETING INFLAMMATORY DISEASES

22.08.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE SECOND QUARTER OF 2018

18.07.18

AMGEN EXERCISES OPT-IN RIGHT IN FIRST PROGRAM FROM MULTIPLE TARGET RESEARCH COLLABORATION WITH NUEVOLUTION

20.06.18

NUEVOLUTION PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

14.06.18

NUEVOLUTION APPROVED FOR LISTING ON NASDAQ STOCKHOLM

28.05.18

RESOLUTIONS AT THE ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

25.05.18

NUEVOLUTION COMPLETES A DIRECTED ISSUE RAISING GROSS PROCEEDS OF SEK 110M

24.05.18

NUEVOLUTION CONTEMPLATES A DIRECTED SHARE ISSUE TO CONTINUE EXPANSION AND ADVANCEMENT OF ITS PIPELINE

08.05.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FIRST QUARTER OF 2018 AND PROVIDES UPDATE ON PARTNERSHIP DISCUSSIONS

26.04.18

NUEVOLUTION OBTAINS NEW DATA IN ITS INTERNAL RORγT PROGRAM SUPPORTING EFFECT IN HUMAN INFLAMMATORY BOWEL DISEASES (IBD)

24.04.18

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

24.04.18

NUEVOLUTION’S BOARD OF DIRECTORS TO BE REDUCED FROM SIX TO FIVE MEMBERS. FREDRIK ARP NOT TO SEEK RE-ELECTION

26.02.18

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2017 – CORRECTION OF ENGLISH VERSION

23.02.18

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2017 NOW AVAILABLE

08.02.18

NUEVOLUTION AB (PUBL) ANNOUNCES ITS YEAR-END REPORT FOR 2017 AND REPORT FOR THE THREE-MONTH PERIOD ENDED 31 DECEMBER 2017

03.01.18

NUEVOLUTION TO RECEIVE LICENSE FEE PAYMENT OF USD 750,000

08.12.17

THE DANISH EASTERN HIGH COURT REVOKES THE MARITIME AND COMMERCIAL HIGH COURT’S DECISION OF 22 FEBRUARY 2016 IN FAVOUR OF NUEVOLUTION’S REQUEST

27.11.17

NUEVOLUTION TO PRESENT NEW DATA ON ITS BET BD1 PROGRAM SUPPORTING EFFECT IN PSORIASIS/ATOPIC DERMATITIS

20.11.17

NOTICE OF EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

07.11.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS REPORT FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2017

03.11.17

NUEVOLUTION APPOINTS JOHNNY STILOU AS DIRECTOR OF INVESTOR RELATIONS AND CORPORATE COMMUNICATION

30.10.17

FREDRIK ARP IS PROPOSED AS BOARD MEMBER IN NUEVOLUTION AB (PUBL)

27.10.17

NUEVOLUTION TO PRESENT NEW DATA ON ITS BET BD1 PROGRAM SUPPORTING THE UNDERSTANDING OF THE BIOLOGICAL MODE-OF-ACTION

18.09.17

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2016/17 NOW AVAILABLE

18.09.17

NUEVOLUTION AB (PUBL) INTENDS TO MOVE THE LISTING OF ITS SHARES TO NASDAQ STOCKHOLM’S MAIN MARKET DURING THE FISCAL YEAR 2017/18

12.09.17

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

06.09.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2016/17

30.08.17

CORRECTION OF: NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

30.08.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

19.06.17

NUEVOLUTION PRESENTS ADDITIONAL POSITIVE ANIMAL RESULTS IN LUPUS FROM ITS BET SELECTIVE PROGRAM

12.06.17

NUEVOLUTION TO PRESENT AT ANGLO-NORDIC MEDICINAL CHEMISTRY SYMPOSIUM

17.05.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE THIRD QUARTER 2016/17

10.05.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE THIRD QUARTER RELEASE AND WEBCAST

20.03.17

BIOEUROPE SPRING 2017 PRESENTATION OF PROGRESS IN THREE PIPELINE PROGRAMS

06.03.17

NUEVOLUTION ANNOUNCES FURTHER TECHNOLOGY ACCESS FEE PAYMENT FROM ITS DRUG DISCOVERY COLLABORATION WITH JANSSEN

14.02.17

NUEVOLUTION TECHNOLOGY PROGRESS: NUEVOLUTION SCALES ITS COMPOUND COLLECTION TO 40 TRILLION USING ITS CHEMETICS™ DRUG DISCOVERY PLATFORM

08.02.17

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE SECOND QUARTER 2016/17

02.02.17

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE SECOND QUARTER RELEASE AND WEBCAST

23.01.17

NUEVOLUTION ANNOUNCES THE PUBLICATION OF A SCIENTIFIC ARTICLE IN COLLABORATION WITH NOBEL LAUREATE DR. ROBERT J. LEFKOWITZ

12.12.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH ALMIRALL

12.12.16

ALMIRALL AND NUEVOLUTION ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP RORγt INHIBITORS FOR TREATMENT OF DERMATOLOGY DISEASES AND PSORIATIC ARTHRITIS

02.12.16

NUEVOLUTION RECEIVES RESEARCH GRANT AND ENTERS COLLABORATION ON DEVELOPMENT OF NEW TAILORED CANCER THERAPEUTICS

17.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FIRST QUARTER 2016/17

11.11.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FIRST QUARTER RELEASE AND WEBCAST

08.11.16

NUEVOLUTION TO PRESENT AT UPCOMING INVESTOR CONFERENCES

04.10.16

CONFERENCE CALL TO DISCUSS THE STRATEGIC COLLABORATION WITH AMGEN

04.10.16

NUEVOLUTION ANNOUNCES STRATEGIC COLLABORATION WITH AMGEN IN ONCOLOGY AND NEUROSCIENCE

22.09.16

ORAL PRESENTATION OF PRECLINICAL AND PRELIMINARY TOXICOLOGY DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

16.09.16

PRESENTATION OF PRECLINICAL DATA ON ITS BET BD1 PROGRAM AT DISCOVERY ON TARGET 2016

15.09.16

NUEVOLUTION AB (PUBL) ANNUAL REPORT 2015/16 NOW AVAILABLE

06.09.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2015/16

05.09.16

NOTICE OF ANNUAL GENERAL MEETING OF NUEVOLUTION AB (PUBL)

29.08.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE FOURTH QUARTER RELEASE AND WEBCAST

25.08.16

PRESENTATION OF DISCOVERY DATA FROM THE GRP78 INHIBITOR PROGRAM AT EFMC-ISMC 2016

23.08.16

NUEVOLUTION TO PRESENT AT THE 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE

16.08.16

PRESENTATION OF PRECLINICAL DATA FROM RORƴt INVERSE AGONIST PROGRAM AT ICI 2016

01.07.16

EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

01.06.16

NOTICE OF EXTRAORDINARY GENERAL MEETING OF NUEVOLUTION AB (PUBL)

20.05.16

REPLAY OF TWO INVESTOR PRESENTATIONS AVAILABLE

11.05.16

Q3 2015/16 QUARTERLY REPORT WEBCAST AND PRESENTATION

10.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS QUARTERLY RESULTS FOR THE THIRD QUARTER 2015/16

06.05.16

NUEVOLUTION AB (PUBL) ANNOUNCES TIMING FOR THE THIRD QUARTER RELEASE AND WEBCAST

20.04.16

NUEVOLUTION ANNOUNCES FURTHER TECHNOLOGY ACCESS FEE PAYMENT FROM ITS DRUG DISCOVERY COLLABORATION WITH JOHNSON & JOHNSON INNOVATION

04.03.16

THE EUROPEAN PATENT OFFICE ISSUES FOUR PATENTS TO NUEVOLUTION AB (PUBL)

22.02.16

THE DANISH SØ- OG HANDELSRETTEN ISSUES A DECISION ON SEPARATE QUESTIONS IN THE CASE BETWEEN NUEVOLUTION AND HENRIK PEDERSEN/CHEMGENE HOLDING APS

22.02.16

NUEVOLUTION AB (PUBL) ANNOUNCES MILESTONE PAYMENT FROM BIG PHARMA COLLABORATION

04.02.16

NUEVOLUTION AB (PUBL) ANNOUNCES ITS QUARTERLY RESULTS FOR THE SECOND QUARTER 2015/16

02.02.16

CHANGE IN NUEVOLUTION’S BOARD OF DIRECTORS